Wolfson CARD, King's College London, SE1 1UL, UK.
Department of Cell Biology and Pathology, Institute of Neurosciences Castilla y León, University of Salamanca, Salamanca, 37007, Spain; Institute of Biomedical Research of Salamanca, Salamanca, 37007, Spain.
Osteoarthritis Cartilage. 2018 Jan;26(1):84-94. doi: 10.1016/j.joca.2017.08.006. Epub 2017 Aug 24.
Aiming to delineate novel neuro-immune mechanisms for NGF/TrkA signalling in osteoarthritis (OA) pain, we evaluated inflammatory changes in the knee joints following injection of monoiodoacetate (MIA) in mice carrying a TrkA receptor mutation (P782S; TrkA KI mice).
In behavioural studies we monitored mechanical hypersensitivity following intra-articular MIA and oral prostaglandin D (PGD) synthase inhibitor treatments. In immunohistochemical studies we quantified joint mast cell numbers, calcitonin gene-related peptide expression in synovia and dorsal root ganglia, spinal cord neuron activation and microgliosis. We quantified joint leukocyte infiltration by flow cytometry analysis, and PGD generation and cyclooxygenase-2 (COX-2) expression in mast cell lines by ELISA and Western blot.
In TrkA KI mice we observed rapid development of mechanical hypersensitivity and amplification of dorsal horn neurons and microglia activation 7 days after MIA. In TrkA KI knee joints we detected significant leukocyte infiltration and mast cells located in the vicinity of synovial nociceptive fibres. We demonstrated that mast cells exposure to NGF results in up-regulation of COX-2 and increase of PGD production. Finally, we observed that a PGD synthase inhibitor prevented MIA-mechanical hypersensitivity in TrkA KI, at doses which were ineffective in wild type (WT) mice.
Using the TrkA KI mouse model, we delineated a novel neuro-immune pathway and suggest that NGF-induced production of PGD in joint mast cells is critical for referred mechanical hypersensitivity in OA, probably through the activation of PGD receptor 1 in nociceptors: TrkA blockade in mast cells constitutes a potential target for OA pain.
旨在描绘神经免疫机制在骨关节炎(OA)疼痛中的新型神经免疫机制,我们评估了在携带 TrkA 受体突变(P782S;TrkA KI 小鼠)的小鼠膝关节注射单碘乙酸(MIA)后膝关节的炎症变化。
在行为研究中,我们监测了关节内 MIA 注射和口服前列腺素 D(PGD)合酶抑制剂治疗后机械性超敏反应的变化。在免疫组织化学研究中,我们定量了关节肥大细胞数量、滑膜和背根神经节中降钙素基因相关肽的表达、脊髓神经元激活和小胶质细胞增生。我们通过流式细胞术分析定量关节白细胞浸润,通过 ELISA 和 Western blot 定量肥大细胞系中 PGD 的生成和环氧化酶-2(COX-2)的表达。
在 TrkA KI 小鼠中,我们观察到 MIA 后 7 天机械超敏反应迅速发展,背角神经元和小胶质细胞激活增强。在 TrkA KI 膝关节中,我们检测到明显的白细胞浸润和位于滑膜伤害感受纤维附近的肥大细胞。我们证明,肥大细胞暴露于 NGF 导致 COX-2 的上调和 PGD 生成的增加。最后,我们观察到 PGD 合酶抑制剂在 TrkA KI 中预防 MIA 机械超敏反应,而在野生型(WT)小鼠中无效。
使用 TrkA KI 小鼠模型,我们描绘了一种新型的神经免疫途径,并表明关节肥大细胞中 NGF 诱导的 PGD 产生对于 OA 中的牵涉性机械超敏反应至关重要,可能是通过伤害感受器中 PGD 受体 1 的激活:肥大细胞中的 TrkA 阻断构成了 OA 疼痛的潜在治疗靶点。